Biotech

All Articles

Pfizer takes $230M struck after axing failed DMD genetics therapy

.Pfizer's phase 3 Duchenne muscular dystrophy (DMD) genetics treatment failure has actually blown a ...

AC Immune finds 'spots' potential in Alzheimer's medication information

.After much more than 20 years of work on neurodegenerative diseases, Swiss biotech AC Immune system...

GSK drops ph. 2 HPV vaccination over lack of best-in-class possible

.GSK has actually junked a phase 2 individual papillomavirus (HPV) vaccine coming from its pipe afte...

OS Therapies refiles $6M IPO to cash HER2 medicine, preclinical ADCs

.OS Therapies are going to detail on the NYSE American inventory exchange today through a $6.4 milli...

ALX's fizzling CD47 action rate sends out sell spiraling down

.ALX Oncology's phase 2 stomach cancer cells response fee has actually deteriorated. After finding i...

Ionis axes eye disease coming from intendeds of Roche-partnered possibility after records let down

.An Additional of Ionis Pharmaceuticals' vital midphase readouts has actually fallen short of assump...

Biogen's CEO pointed out no risky deals in 2023. He's ready to become strong

.While Biogen's pharma peers are actually seeking for late-stage assets along with little bit of thr...

Instil refills pipeline in $2B biobucks handle ImmunOnco

.Instil Bio has been a biotech in search of a pipe after it junked its lead assets over the last num...

Biogen bows out Denali Alzheimer's collab

.Biogen has actually handed back civil rights to an early Alzheimer's ailment system to Denali Thera...

Takeda faucets brand-new mind of US oncology business-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of significant leadership hirings, firings and a...